In brief, these findings extend the existing literature that indicates that GluN2A is involved in the effects of ketamine on ameliorating symptoms of treatment-resistant depression and may have implications for understanding the cellular and molecular mechanisms underlying the antidepressant effects of ketamine (Figure 8). Here, GRIN2A is linked to major depressive disorder.